Brian Kaspar's head was among the first to roll on Novartis after business administrators realized that manipulated data had been included in the application for Zurtherma, now the world's most expensive therapy.
But in his first public response, the scientific founder of AveXis – bought by Novartis for $ 8.7 billion – shoots back. And he says that not only is he not involved in any wrongdoing, he is ready to defend his name as needed.
I reached out to Brian Kaspar after Novartis said that he and his brother Allen had been bullied in mid-May two months after the company became aware of the allegations related to tampered data. His response came back through his lawyers.
Basic subscription required
Instantly unlock this story and join 57,500+ biopharma professionals who read Endpoints daily ̵